期刊
ANNALS OF ONCOLOGY
卷 28, 期 8, 页码 1832-1835出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdx266
关键词
tumour-infiltrating lymphocytes; neoadjuvant chemotherapy; breast cancer; predictive; computational pathology
类别
资金
- Cancer Research UK [CRUK/08/037]
- Roche
- Sanofi-Aventis
- MRC [MR/M008975/1] Funding Source: UKRI
- Academy of Medical Sciences (AMS) [AMS-SGCL11-Ali] Funding Source: researchfish
- Cancer Research UK [16561, 16942, 11010] Funding Source: researchfish
- Cancer Research UK
- The Francis Crick Institute [10124] Funding Source: researchfish
- Medical Research Council [MR/P012442/1, MR/M008975/1] Funding Source: researchfish
- National Institute for Health Research [CL-2013-14-006, NF-SI-0611-10154, NF-SI-0515-10090] Funding Source: researchfish
Background: We have previously shown lymphocyte density, measured using computational pathology, is associated with pathological complete response (pCR) in breast cancer. The clinical validity of this finding in independent studies, among patients receiving different chemotherapy, is unknown. Patients and methods: The ARTemis trial randomly assigned 800 women with early stage breast cancer between May 2009 and January 2013 to three cycles of docetaxel, followed by three cycles of fluorouracil, epirubicin and cyclophosphamide once every 21 days with or without four cycles of bevacizumab. The primary endpoint was pCR (absence of invasive cancer in the breast and lymph nodes). We quantified lymphocyte density within haematoxylin and eosin (H&E) whole slide images using our previously described computational pathology approach: for every detected lymphocyte the average distance to the nearest 50 lymphocytes was calculated and the density derived from this statistic. We analyzed both pre-treatment biopsies and post-treatment surgical samples of the tumour bed. Results: Of the 781 patients originally included in the primary endpoint analysis of the trial, 609 (78%) were included for baseline lymphocyte density analyses and a subset of 383 (49% of 781) for analyses of change in lymphocyte density. The main reason for loss of patients was the availability of digitized whole slide images. Pre-treatment lymphocyte density modelled as a continuous variable was associated with pCR on univariate analysis (odds ratio [OR], 2.92; 95% CI, 1.78-4.85; P<0.001) and after adjustment for clinical covariates (OR, 2.13; 95% CI, 1.24-3.67; P = 0.006). Increased pre- to post-treatment lymphocyte density showed an independent inverse association with pCR (adjusted OR, 0.1; 95% CI, 0.033-0.31; P<0.001). Conclusions: Lymphocyte density in pre-treatment biopsies was validated as an independent predictor of pCR in breast cancer. Computational pathology is emerging as a viable and objective means of identifying predictive biomarkers for cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据